{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T18:22:18Z","timestamp":1772994138960,"version":"3.50.1"},"reference-count":21,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":345,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Case Reports in Hematology"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>Patients with multiple myeloma (MM) have an inherent risk for secondary myeloid malignancies. Innovative approaches to treatment are needed when these hematologic malignancies co\u2010occur. Venetoclax (VEN), a BCL2 inhibitor, has been used in combination with Azacitidine in acute myeloid leukemia, in the trial setting in high\u2010risk myelodysplastic syndrome (MDS), and in t(11; 14) MM in the salvage setting. Here, we present a case report of concurrent treatment of high\u2010risk MDS and t(11; 14) MM in a patient, using VEN\u2010based therapy. Following diagnosis with IgG t(11; 14) MM, the patient received treatment with Lenalidomide, Bortezomib, and Dexamethasone and achieved a very good partial response. She subsequently proceeded to autologous stem cell transplant and thereafter continued on Lenalidomide maintenance. Relapsed disease was noted 3\u2009years following transplant, with a concurrent diagnosis of a high\u2010risk MDS (mutations in NRAS and DNMT3A). Given the known efficacy of VEN in her concomitant malignancies, we elected to use a VEN\u2010based regimen, at a lower dose of VEN than has been shown to be efficacious in t(11; 14) MM. Bone marrow biopsy demonstrated response from the perspective of both malignancies, until she had relapsed disease with a mixed phenotype acute leukemia \u223c 19\u2009months after relapsed MM\/diagnosis of high\u2010risk MDS. Overall, this case demonstrates successful treatment of both hematologic malignancies at a lower dose of VEN than previously shown to be efficacious in t(11; 14) MM.<\/jats:p>","DOI":"10.1155\/crh\/6491283","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T10:20:01Z","timestamp":1765534801000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of Relapsed\/Refractory t(11;14) Multiple Myeloma and High\u2010Risk Myelodysplastic Syndrome With Venetoclax"],"prefix":"10.1155","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8797-9853","authenticated-orcid":false,"given":"Allison O.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Clune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JoAnn","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-5605","authenticated-orcid":false,"given":"Cristina","family":"Gasparetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0546-7895","authenticated-orcid":false,"given":"Thomas W.","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"e_1_2_10_1_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355743"},{"key":"e_1_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.06.015"},{"key":"e_1_2_10_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2012971"},{"key":"e_1_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2021.39.15_suppl.tps7054"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30525-8"},{"key":"e_1_2_10_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26083"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.7510"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283472"},{"key":"e_1_2_10_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.07.029"},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100757"},{"key":"e_1_2_10_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2020.101144"},{"key":"e_1_2_10_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04775-1"},{"key":"e_1_2_10_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw606"},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.064121"},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-140532"},{"key":"e_1_2_10_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2020.100202"},{"key":"e_1_2_10_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/s2152-2650(25)02083-x"},{"key":"e_1_2_10_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007959"},{"key":"e_1_2_10_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025409"},{"key":"e_1_2_10_20_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1577908"},{"key":"e_1_2_10_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2024.100469"}],"container-title":["Case Reports in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/crh\/6491283","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/crh\/6491283","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/crh\/6491283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T15:05:17Z","timestamp":1772982317000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/crh\/6491283"}},"subtitle":[],"editor":[{"given":"Pier Paolo","family":"Piccaluga","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1155\/crh\/6491283"],"URL":"https:\/\/doi.org\/10.1155\/crh\/6491283","archive":["Portico"],"relation":{},"ISSN":["2090-6560","2090-6579"],"issn-type":[{"value":"2090-6560","type":"print"},{"value":"2090-6579","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2025-05-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"6491283"}}